Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02454114
Other study ID # 12/NW/0731
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 2013
Est. completion date January 2015

Study information

Verified date October 2012
Source Liverpool University Hospitals NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

HOME FIRST (Home Followed - up with Infection Respiratory Support Team) is an early supported discharge scheme. It will enable patients with lower respiratory tract infection (LRTI) to be provided with high quality safe, effective, efficient patient centred care, tailored to their needs in their own home; aiming to improve the overall experience of the service user, improve patient outcomes and reduce hospital length of stay whilst simultaneously reducing admission rates, an area of major strategic importance to the NHS.


Description:

A randomised interventional clinical care pathway study of early supported discharge (termed 'HOME FIRST') versus standard hospital care for patients hospitalised with LRTI. HOME FIRST will provide co-ordinated multidisciplinary team (MDT) care, provision of 24hr emergency telephone cover, access to fully trained respiratory study nurse(s) and study doctor(s). The HOME FIRST MDT consists of: - Study doctors (trained respiratory physicians - consultants and senior SpRs) - Highly trained respiratory specialist nursing staff - Close links with a physiotherapist (mobility and respiratory) - Home help provision (temporary assistance with ADLs by carers) which may include occupational therapy or social worker involvement (HOME FIRST has fast access to meals-on-wheels) - Close links with pharmacy for rapid dispensing of discharge medication. Patients hospitalised with LRTI at the Royal Liverpool and Broadgreen (RLBUHT) Teaching Hospitals between October 2012 and April 2014 will be approached. Patients (or the next of kin if the patient is unable to give informed consent) will be offered participation in the study if they fit the strict inclusion/exclusion criteria. They will be then be randomised to receive HOME FIRST or standard hospital care (SHC). The investigators will aim to recruit 25 patients to each arm of the study. Patients randomised to HOME FIRST care will initially receive up to twice daily respiratory specialist nurse visits for the first 48 hours. After this time period, the frequency and duration of visits will depend on clinical need. The study nurse will establish the need for the involvement of other MDT team members. Laboratory tests will be performed as clinically indicated at the discretion of the study team. Venepuncture will be performed by fully trained research staff for clinical purposes as needed in the HOME FIRST limb: as for those patients in the SHC limb frequency of venepuncture depends on clinical assessment of need by their regular medical team. Patients randomised to standard hospital care (SHC) - All management and discharge decisions will be made by the patient's usual hospital team. Clinical tests will be performed at the discretion of the medical team. If any significant or concerning clinical issues are noted during study team's visits, the usual medical team will be alerted. All patients will be discussed at a weekly case-note MDT meeting. All patients will be followed-up on discharge in the 'Respiratory Infection' out-patient clinic (in the patient's own home if necessary) at 6 weeks, with a repeat chest X-ray if needed.


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Eligibility - Patients with any of the following conditions; - Pneumonia - community-acquired (CAP) or hospital-acquired (HAP) - pneumonia definition - a series of clinical symptoms with radiological consolidation N.B. All pneumonia CURB-65 scores will be considered but patients with CURB-65 =3 MUST have had at least 24hrs of in-patient observation before recruitment into part B of the study. - Pneumonia with concomitant COPD or bronchiectasis - Non-pneumonic lower respiratory tract infection without COPD or bronchiectasis Inclusion Criteria: - Age>18yrs old - All observations must be stable for 12-24hrs - EWS =2 AND SBP>90 (all observations must be stable for 12-24hrs) - Has a telephone - Can manage activities of daily living with current available support (If needed, immediate occupational therapy/physiotherapy/social assessment and care can be arranged prior to discharge and continued at home) - Improving/stable inflammatory markers - Improving/stable U&Es - Fluent English speaker Exclusion Criteria; - Acute exacerbations of COPD - Acute exacerbations of bronchiectasis without consolidation - Patients with CURB-65 >3 admitted <24 hours ago - Patients unable to manage at home even with maximal support from HOME FIRST (This may include intravenous drug users, patients with history of excess alcohol consumption or mental health problems) - Empyema or untapped pleural effusion (If no diagnostic pleural tap performed - discuss with study doctor) - Serious co-morbidities requiring hospital treatment (e.g. CKD, CCF) or deemed unstable (significant AKD) - Suspected MI/raised TnI/T consistent with NSTEMI (Or acute ECG changes) within 5 days of discharge - Empyema or complicated parapneumonic effusion - SBP<90mmHg - Neutropenia - No fixed abode - Tuberculosis suspected - Well enough for discharge without HOME FIRST support - Oxygen saturations <92% on air - for patients without chronic respiratory illness Oxygen saturations <88% on air - for patients with chronic respiratory illness (excluding asthma for which oxygen saturations must be >92% on air). All such cases MUST be discussed as oxygen assessment may be needed

Study Design


Intervention

Other:
HOMEFIRST
HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
Standard Hospital Care
No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team. SF-12 (physical and mental function) [performed twice in total] - at recruitment (day 0) and 6 weeks CAP-SYM [performed 3 times in total] - at recruitment day 0 (twice including day minus 30) and 6 weeks Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor.

Locations

Country Name City State
United Kingdom Royal Liverpool And Broadgreen University Hospital Liverpool Merseyside

Sponsors (2)

Lead Sponsor Collaborator
Liverpool University Hospitals NHS Foundation Trust Liverpool School of Tropical Medicine

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Health - economic A formal planned health economic analysis (by an NIHR Research Design Service [RDS] recommended health-economist) will measure costs and resource utilisation, using costs that are sensitive to the different resources used during each care episode, to assess the cost-effectiveness of HOME FIRST. One year
Primary Time to recovery Our primary endpoint is time to recovery. This is assessed by our simple 'RECRTI' (functional RECovery from Respiratory Tract Infection) questionnaire (non-validated) which is completed at 6 weeks Patients (or consultees) will be asked at recruitment to define their/the patient's best exercise capacity in the last 3 months e.g chair to bed with 1, unlimited exercise tolerance etc
At the 6 week out-patient appointment they will be asked 4 simple questions: (marked on a likert-type scale in days and weeks):
When (if at all) did your sleep return to normal?
When (if at all) did your diet/appetite return to normal?
When (if at all) did your (pre-defined) exercise capacity return to normal?
When (if at all) did your capacity to work or socialise (delete as appropriate) return to normal?
With regards to the primary outcome of time to recovery, this is a non-inferiority trial.
Six weeks
Secondary 30-day mortality We will assess safety i.e. ensure there is no increase in mortality in the HOME FIRST limb. up to 6 weeks after recruitment
Secondary 30-day hospital readmission rates We will assess safety i.e. ensure there is no delayed recovery, no pneumonia (or non-pneumonia) complications resulting in hospital admission in the HOME FIRST arm. up to 6 weeks after recruitment
Secondary Patient satisfaction using a validated satisfaction questionnaire A validated patient satisfaction will be conducted at 2 weeks by an independent assessor. at 2 weeks post recruitment
Secondary Carer (NOK) satisfaction using a validated satisfaction questionnaire A validated carer/consultee satisfaction will be conducted at 2 weeks by an independent assessor. at 2 weeks post recruitment
Secondary Length of stay in hospital Length of hospital stay will be calculated. Participants will be followed for the duration of hospital stay, this may be 1 day to 1 year
Secondary Functional status as assessed by SF-12 validated questionnaire Functional status (physical and mental) and quality of life (QOL) questionnaire will be completed to assess recovery / post respiratory infection. up to 6 weeks after recruitment
Secondary Pneumonia score as assessed by CAP-SYM validated questionnaire The questionnaire will be completed to assess recovery / post respiratory infection up to 6 weeks after recruitment
Secondary Combined total length of stay (days) - hospital and home first Total length of stay - combined will be calculated Participants will be followed for the duration of hospital stay and their HOME FIRST stay, the latter can range from 1 - 5 days
See also
  Status Clinical Trial Phase
Completed NCT02559310 - Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Phase 3
Completed NCT01530763 - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Phase 2/Phase 3
Completed NCT02517489 - Community-Acquired Pneumonia : Evaluation of Corticosteroids Phase 3
Not yet recruiting NCT01937832 - A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia Phase 3
Completed NCT00653172 - Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia Phase 2
Recruiting NCT02139163 - Epidemiological Study on Community Acquired Pneumonia
Completed NCT03411824 - Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine
Recruiting NCT06210282 - The Effect of Focused Lung Ultrasonography on Antibiotic Prescribing in General Practice N/A
Withdrawn NCT02269644 - A P3 Comparator Trial in Community Acquired Bacterial Pneumonia Phase 3
Recruiting NCT01963442 - Short Duration Treatment of Non-severe Community Acquired Pneumonia Phase 2
Terminated NCT00887276 - Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia Phase 4
Not yet recruiting NCT00390819 - Epidemiology of Community Acquired Pneumonia in North Israel N/A
Completed NCT00079885 - Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia Phase 3
Not yet recruiting NCT04158310 - Evaluation the Clinical Value of Xiyanping Injection in the Treatment of Community-acquired Pneumonia in Children
Recruiting NCT02552342 - Corticosteroid Therapy for Severe Community-Acquired Pneumonia Phase 4
Completed NCT02922387 - Smoking Cessation Intervention in Respiratory Inpatients Phase 4
Completed NCT00467701 - Community Acquired Pneumonia in Telemark and Ostfold N/A
Completed NCT04198571 - Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Completed NCT02107001 - Lung Ultrasound in Pleuritic Chest Pain N/A
Completed NCT01561885 - Collaborative Healthcare Professionals Approach in Monitoring of Patient Centered Outcomes Through Pathways N/A